Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

BACKGROUND: Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab (ALI) and evolocumab (EVO) have previously been evaluated through controlled clinical trials with selective patient groups. Post-commercially, in patients with heterozygous familial hyperc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Parth, Glueck, Charles J., Goldenberg, Naila, Min, Sarah, Mahida, Chris, Schlam, Ilana, Rothschild, Matan, Huda, Ali, Wang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259842/
https://www.ncbi.nlm.nih.gov/pubmed/28115017
http://dx.doi.org/10.1186/s12944-017-0416-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259842/
https://www.ncbi.nlm.nih.gov/pubmed/28115017
http://dx.doi.org/10.1186/s12944-017-0416-7

Ejemplares similares